Artificial Intelligence
BioXcel Therapeutics to Host Virtual Key Opinion Leader Event to Highlight BXCL501 as a Potential Treatment for Agitation and Opioid Withdrawal Symptoms
NEW HAVEN, Conn., Feb. 12, 2021 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that the Company will host a virtual Key Opinion Leader (“KOL”) event on Friday, February 19, 2021 from 11:00 am ET to 2:00 pm ET. The event aims to highlight BXCL501, the Company’s investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine (“Dex”), and its potential as a treatment option for multiple neuropsychiatric conditions.
BioXcel’s management team will be joined by leading experts for each indication to discuss the significant unmet medical need and BXCL501’s potential to change the treatment paradigm.
KOL Presenters Include:
Schizophrenia/Bipolar Related Agitation
- Scott Zeller, MD, is an Assistant Clinical Professor of Psychiatry at the University of California-Riverside and Touro University medical schools. He served as Chief of Psychiatric Emergency Services of the Alameda Health System for twenty years, as well as founded Project BETA, which revolutionized the care approach for agitated individuals worldwide; he has also authored several books and numerous research articles on Agitation. Dr. Zeller is the Past President of the American Association for Emergency Psychiatry and Past Chair of the multidisciplinary National Coalition on Psychiatric Emergencies.
Dementia Related Agitation
- Alan Breier, MD, is a Mental Health Research and Education Senior Professor of Psychiatry at Indiana University School of Medicine. Additionally, at the University, he is Vice-Chair for Clinical Research, the Chief of IU Psychotic Disorders Program, and the Director of the Prevention and Recovery Center for Early Psychosis. Previously, he served as the Chief Medical Officer and Vice President of Pharmaceutical Products at Eli Lilly, where he was also the product team leader for the antipsychotic drug Zyprexa®.
- Larry Ereshefsky, PharmD, FCCP, BCPP, is a founding member of the International Society for CNS Clinical Trials and Methodology, serving as Chair of the Behavioral and Psychological Symptoms of Dementia Steering Committee and Co-Chaired the Agitation and Apathy sub-groups. He is a retired Regents Professor of Pharmacy, Psychiatry, and Pharmacology at the University of Texas/UT Health Science Center and has designed and conducted more than 80 CNS clinical trials evaluating treatments for Alzheimer’s and other neurodegenerative disorders, contributing to several drug approvals spanning neurology and psychiatry. He serves as the Chief Scientific Officer for APEX Innovative Sciences and for Follow the Molecule LLC, where he focuses on translational drug development strategies.
Opioid Withdrawal Symptoms
- Thomas R. Kosten, MD, is the JH Waggoner Chair and Professor of Psychiatry, Pharmacology, Immunology, Pathology, and Neuroscience of the Dan Duncan Institute for Clinical and Translational Research at Baylor College of Medicine. He has directed a national NIDA Medications Development Center since 1988, was previously the Research Director of the VA National Substance Use Disorders Quality Enhancement Research Initiative at the Michael E. DeBakey VA Medical Center and is the founder of the Division of Substance Abuse at Baylor College of Medicine and at Yale University School of Medicine.
Delirium Related Agitation
- E. Wesley Ely, MD, MPH, is a subspecialist in Pulmonary and Critical Care Medicine who conducts health services research as a Professor of Medicine in the Division of Allergy, Pulmonary, and Critical Care Medicine at Vanderbilt University Medical Center. He is a practicing intensivist with a focus on Geriatric ICU Care, as the Associate Director for Research for the VA Tennessee Valley Geriatric Research and Education Clinical Center. Dr. Ely is also the co-director of the Center for Critical Illness, Brain Dysfunction, and Survivorship, where his team developed the primary tool used to measure delirium clinically and in ICU-based trials.
A live webcast of the event will be accessible through the Investors section of the Company’s website at www.bioxceltherapeutics.com on February 19th at 11:00 am ET. Following the event, the webcast will be archived on the Company’s website for at least 30 days.
About BXCL501
BXCL501 is an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of agitation and opioid withdrawal symptoms. BioXcel believes that BXCL501 directly targets a causal agitation mechanism, and the Company has observed anti-agitation results in multiple clinical studies across several neuropsychiatric disorders. BXCL501 has been granted Fast Track Designation by the U.S. Food and Drug Administration for the acute treatment of agitation in patients with schizophrenia, bipolar disorders, and dementia. BXCL501 has been studied in two Phase 3 trials (SERENITY I and II) for the acute treatment of schizophrenia related agitation and bipolar disorder related agitation, respectively, and in a Phase 1b/2 trial (TRANQUILITY) for the acute treatment of dementia related agitation. This product candidate is also currently being evaluated in a Phase 1b/2 study (RELEASE) for the treatment of opioid withdrawal symptoms, with plans to initiate a Phase 2 trial in hospitalized patients suffering from delirium related agitation within the next several months.
BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel’s two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. For more information, please visit www.bioxceltherapeutics.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to BXCL501’s potential as a treatment option for multiple neuropsychiatric conditions. When used herein, words including “anticipate,” “being,” “will,” “plan,” “may,” “continue,” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon BioXcel’s current expectations and various assumptions. BioXcel believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain.
BioXcel may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its limited experience in drug discovery and drug development; its dependence on the success and commercialization of BXCL501 and BXCL701 and other product candidates; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; undesirable side effects caused by BioXcel’s product candidates; its approach to the discovery and development of product candidates based on EvolverAI is novel and unproven; its exposure to patent infringement lawsuits; its ability to comply with the extensive regulations applicable to it; impacts from the COVID-19 pandemic; its ability to commercialize its product candidates; and the other important factors discussed under the caption “Risk Factors” in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investors section of our website at www.bioxceltherapeutics.com.
These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While BioXcel may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing BioXcel’s views as of any date subsequent to the date of this press release.
Contact Information:
BioXcel Therapeutics, Inc.
Investor Relations:
Mary Coleman
BioXcel Therapeutics, VP of Investment Relations
[email protected]
1.475.238.6837
John Graziano
Solebury Trout
[email protected]
1.646.378.2942
Media:
Julia Deutsch
Solebury Trout
[email protected]
1.646.378.2967
Artificial Intelligence
Rockwell Automation and its PartnerNetwork™ Ecosystem Present Artificial Intelligence, Autonomous Operations, 5G and Cybersecurity in Driving Digital Transformation at Hannover Messe 2024
In collaboration with partners including Cisco, Ericsson, Microsoft, ODVA, the OPC Foundation and NVIDIA, Rockwell will showcase the latest technologies shaping the future of industrial operations
DUSSELDORF, Germany, April 18, 2024 /PRNewswire/ — Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, will showcase its innovative, industry-leading technology and services with its partners, including Microsoft and Cisco, at the Hannover Messe 2024 trade fair, April 22-26, in Hannover, Germany.
Rockwell will collaborate with its PartnerNetwork™ ecosystem and demonstrate solutions that address a variety of challenges for industrial companies, including modernizing operations, achieving sustainability goals and accelerating digital transformation.
“Our partnerships embody a shared vision of building and delivering the best solutions to drive digital transformation in industry and enable intelligent factories,” said Malte Dieckelmann, vice president, enterprise software sales, Europe, Middle East and Africa, Rockwell Automation. “We do this by simplifying how manufacturers design, operate and maintain their operations and empower their people in a secure, connected enterprise.”
In collaboration with Cisco, Ericsson, Microsoft, ODVA, the OPC Foundation and NVIDIA, Rockwell will present technology and services that help solve complex challenges with solutions for the entire value chain of a digital transformation journey.
Artificial intelligence (AI), autonomous operations, 5G and cybersecurity are among key technologies that help manufacturers accelerate their digital transformation. According to Rockwell’s recently published 9th annual “State of Smart Manufacturing Report,” industrial companies around the world cite artificial intelligence as their top priority for new investment over the next 12 months.
At the Microsoft booth, visitors will see the latest technology integrations between the two companies, including how AI is transforming manufacturing through a customer-inspired digital twin of a quality inspection process using artificial intelligence, highlighted by a real-world simulation of product sorting and autonomous material handling.
Following a recently announced collaboration with NVIDIA, Rockwell will share how it is integrating NVIDIA Omniverse Cloud application programming interfaces (APIs) into Emulate3D by Rockwell Automation, bringing users data interoperability, live collaboration and physically based visualization for designing, building and operating industrial-scale digital twins of production systems.
At the Cisco booth, Rockwell will present how the two companies enable a secure connected industrial environment leveraging Rockwell’s Converged Plantwide EthernetTM reference architecture (CPwE) with its co-developed industrial ethernet switching, as well as cybersecurity solutions such as Cisco® Cyber Vision, which enables network segmentation, asset discovery and security monitoring.
Rockwell will highlight its collaboration with Ericsson by demonstrating Plex Asset Performance Management (APM) – enabled by industrial private 5G connectivity – driving real-time decision-making and managing new assets such as autonomous mobile robots (AMRs). Private 5G allows manufacturers to be more agile, flexible and sustainable while adding more devices and intelligence to their networks.
Rockwell is also partnering with ODVA, a standards development organization, to demonstrate the benefits of EtherNet/IP, CIP Security™ and 5G. Reliable wireless industrial automation appliances using EtherNet/IP and CIP Safety in private 5G networks will be shown. Also on display will be recent wireless device additions to Rockwell’s EtherNet/IP product portfolio.
Finally, Rockwell will be at the booth of OPC Foundation, an industry group that maintains standards for the secure and reliable information exchange in industrial applications. Rockwell offers scalable OPC UA solutions for machine builders and end users through Embedded Edge Compute Modules and the FactoryTalk® Optix™ software platform, supporting heterogeneous software applications and control environments.
About Rockwell AutomationRockwell Automation, Inc. (NYSE: ROK), is a global leader in industrial automation and digital transformation. We connect the imaginations of people with the potential of technology to expand what is humanly possible, making the world more productive and more sustainable. Headquartered in Milwaukee, Wisconsin, Rockwell Automation employs approximately 29,000 problem solvers dedicated to our customers in more than 100 countries. To learn more about how we are bringing Connected Enterprise to life across industrial enterprises, visit www.rockwellautomation.com.
Logo – https://mma.prnewswire.com/media/1981317/Rockwell_Automation_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/rockwell-automation-and-its-partnernetwork-ecosystem-present-artificial-intelligence-autonomous-operations-5g-and-cybersecurity-in-driving-digital-transformation-at-hannover-messe-2024-302119837.html
Artificial Intelligence
LG STRENGTHENS EUROPEAN PRESENCE WITH ITS KITCHEN SOLUTIONS SHOWCASE AT MDW 2024
Featuring Advanced AI Technologies and Sleek Design, Company’s Expanded Lineup of Built-in Appliances Brings Outstanding Convenience and Style to the Kitchen
SEOUL, South Korea, April 18, 2024 /PRNewswire/ — LG Electronics (LG) is unveiling its latest built-in kitchen appliances at Milan Design Week (MDW) 2024, taking place in Milan, Italy, from April 16-21. At the center of LG’s Milan showcase are the brand-new Signature Kitchen Suite built-in oven, free zone induction hob, and downdraft hood. Boasting innovative, premium design and highly-convenient features, the company’s refined built-in solutions bring exceptional ease-of-use and effortless elegance to the kitchen.
Signature Kitchen Suite Built-in Oven with Advanced Cooking Technologies
Debuting at MDW 2024 and designed with European consumers in mind, the Signature Kitchen Suite 60-centimeter (24-inch) built-in oven offers a variety of cutting-edge features and AI technologies to elevate the culinary experience. Equipped with Gourmet AI™️, the oven can identify what the user is cooking and automatically select the appropriate cooking mode from 130 recipes. Gourmet AI also enables ‘browning’ control for foods such as pizza and steak, actively keeping tabs on the cooking process and notifying users via the ThinQ™️ app as soon as their food is done. Thanks to video-recognition, LG’s intelligent oven can suggest the optimal settings for the dish being prepared, while real-time video monitoring and time-lapse recording make it easy to check on the progress of one’s meal using the ThinQ app.
Employing enhanced ProBake powered by inverter technology, the new oven delivers uniform heat and fast, efficient cooking with an A++ energy rating. LG’s innovative technology rotates the convection fan back and forth to ensure shorter preheating times, even heating, and crispier results when using the oven’s Air Fry mode. The company’s unique InstaView™️ technology further enhances user convenience, making it possible to see inside simply by knocking twice on the oven door.
Free Zone Induction Hob for Convenient and Flexible Cooking
The Signature Kitchen Suite’s 90-centimeter (36-inch) free zone induction hob presents next-level flexibility and ease-of-use, allowing users to place any size and type of cookware – such as Paella pans and moka pots – anywhere on its cooking surface.* The new appliance can detect and track the position of cookware, eliminating the need to manually cancel and reapply settings when moving a saucepan or skillet from one part of the cooking surface to another. What’s more, the AI technology embedded in the hob can detect the temperature of cookware and automatically lower the heat when necessary, helping to minimize spills and splatter when boiling water or preparing soups and sauces.
Expanded Built-in Lineups for Diverse Kitchen Lifestyles
LG is further bolstering its built-in product lineup with the introduction of the new Signature Kitchen Suite downdraft hood. Made to integrate seamlessly into islands and countertops, the 90-centimeter (36-inch) hood offers a sleek, sophisticated look with its chic black glass and modern frame design. It also provides powerful ventilation, effectively extracting steam and odors for a more pleasant cooking experience.
Additionally, LG has expanded its portfolio of built-in appliances for the European market. Along with new products, such as an 80-centimeter (30-inch) induction hob and built-in combi refrigerators and microwave ovens, the company now provides a wider range of options within its oven lineups – from more product variation to a greater choice of colors and sizes. Among the new models are the Signature Kitchen Suite 122 centimeter (48 inch)-wide French-door refrigerator and stunning appliances from the Transitional lineup, featuring slim handles and satin stainless steel exteriors with a velvety matte finish. To help customers create a curated kitchen aesthetic, the company offers an array of new finishes for its premium built-in products, with black stainless steel and stainless steel joining the previously-introduced black glass finish.
“We are thrilled to showcase our latest built-in innovations at this year’s Milan Design Week, demonstrating our commitment to leading new design trends and meeting the diverse needs of European customers,” said Lyu Jae-cheol, president of LG Electronics Home Appliance & Air Solution Company. “LG will continue to strengthen its presence in Europe through an expanded range of built-in appliances delivering style, performance and convenience in the kitchen.”
Visitors to MDW 2024 in Milan from April 16-21 can experience LG’s latest built-in lineups at the LG booth at Milan Fairgrounds.
* Cookware recognition may vary depending on the size or number of items placed on the surface.
About LG Electronics Home Appliance & Air Solution Company
The LG Home Appliance & Air Solution Company is a global leader in home appliances, air solutions as well as smart home solutions featuring LG ThinQ. The company is creating various solutions with its industry leading core technologies and is committed to making life better and sustainable for consumers and the planet by developing thoughtfully designed kitchen appliances, living appliances, HVAC and air purification solutions. Together, these products deliver enhanced convenience, superb performance, efficient operation and sustainable lifestyle solutions. For more news on LG, visit www.LGnewsroom.com.
Photo – https://mma.prnewswire.com/media/2389542/Signature_Kitchen_Suite_Combi_Steam_Ovens__Induction_hob__Downdraft__hood_Crop_resize.jpg
Photo – https://mma.prnewswire.com/media/2389543/Signature_Kitchen_Suite_Combi_Steam_Ovens.jpg
Photo – https://mma.prnewswire.com/media/2389544/Signature_Kitchen_Suite_Downdraft_Hood.jpg
Photo – https://mma.prnewswire.com/media/2389545/Signature_Kitchen_Suite_Induction_Hob.jpg
View original content:https://www.prnewswire.co.uk/news-releases/lg-strengthens-european-presence-with-its-kitchen-solutions-showcase-at-mdw-2024-302120279.html
Artificial Intelligence
DataTracks Celebrates Completion of 19 Years
SINGAPORE, April 18, 2024 /PRNewswire/ — DataTracks, a provider of cloud-based software to automate/generate compliance reports for filing with financial/security regulators to more than 28,000 business enterprises in 26 countries, celebrates the completion of 19 years of service and innovation. Founded with a vision to make regulatory compliance “accurate, reliable, timely, and easy”, DataTracks has grown into a leading name in the industry, worldwide with cutting edge software that incorporates “artificial intelligence” aided features to reduce “time to prepare” and improve “accuracy”.
Decades of Dedication and Expertise
Over nearly two decades, DataTracks has achieved significant growth, with its software delivering more than 400,000 reports, showcasing its pivotal role in regulatory reporting. The software and service address regulations across diverse jurisdictions, including SEC in the USA, HMRC and FCA in the UK, Revenue in Ireland, CIPC in South Africa, ACRA in Singapore, MCA in India, SSM in Malaysia and ESMA, EBA, and EIOPA in Europe.
DataTracks distinguishes itself in the industry
(a) with its global footprint (preferred by business enterprises whose regulatory obligations are spread across multiple jurisdictions)
(b) with its state-of-the art software that incorporates “AI/ML” features and
(c) with its credentials for information security (including ISO 9001:2015 and ISO 27001:2013 certifications)
Addressing the employees and spouses in a town hall meeting to celebrate the event, Vinod P John, President of DataTracks said: “We are happy to start our 20th year in the industry. I have to thank the 28,000 clients who trust us and the several hundred employees who developed our software and who helped customers (and our internal team) prepare compliance reports for reaching this milestone. We’ve always believed in leveraging technology to make regulatory compliance as easy, quick, timely, and accurate as possible for our clients. Our continuous investment in AI and machine learning is a testament to this belief, and it’s what keeps us at the forefront of the industry.”
Looking ahead, DataTracks is ready to address upcoming mandates such as the DATA Act and FTA in the US as well as the MBRS/XBRL mandate by SSM in Malaysia.
About DataTracks
DataTracks is a Singapore-based globally renowned leader in providing cloud-based regulatory compliance software for self-use and “black box services” using the same software, catering to 28,000 clients across 26 countries. In 19 years DataTracks has helped its client enterprises prepare more than 400,000 compliance reports for filing with financial/security regulators in several jurisdictions. Financial analysts have rated the quality of reports generated using DataTracks as top of industry for quality; significantly above that of several of its competitors. For further information, visit www.datatracks.com.
For Business Enquiries: Email: [email protected]; Phone: Singapore: +6531582850, US: +1(646)9048324, UK: +44(0)2036088035
Media Contact: [email protected]
Logo – https://mma.prnewswire.com/media/663546/3984133/DataTracks_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/datatracks-celebrates-completion-of-19-years-302119623.html
-
Artificial Intelligence5 days ago
In-Depth Analysis of Germany and France Data Center Markets: Germany Poised to Contribute Over $12.24 Billion Opportunities in the Next 6 Years – Arizton
-
Uncategorized6 days ago
Arm CEO Rene Haas will be delivering a Partner’s Event Speech at COMPUTEX 2024
-
Uncategorized6 days ago
BJEI: A New Record of High Performance in 2023 and a New Pattern of Diversified and Coordinated Development
-
Uncategorized6 days ago
Dimethyl Carbonate Market worth $1.9 billion by 2028 – Exclusive Report by MarketsandMarkets™
-
Uncategorized6 days ago
Integrity Food Marketing Joins Forces with CA Ferolie to Expand East Coast Reach from Maine to Florida
-
Artificial Intelligence5 days ago
CogX Festival Set to Debut in Los Angeles at Century Plaza on May 7th, 2024
-
Artificial Intelligence6 days ago
aelf Leads the Fusion of AI and Blockchain to Shape the Future of Technology
-
Artificial Intelligence6 days ago
Xinhua Silk Road: Zoomlion Access pursues high-quality development with aerial work machinery sector innovation